# Safety and Efficacy of Radiation/Cetuximab Plus EGFR Antisense DNA for Head and Neck Squamous Cell Carcinoma

> **NCT00903461** · PHASE1 · TERMINATED · sponsor: **University of Pittsburgh** · enrollment: 7 (actual)

## Conditions studied

- Carcinoma, Squamous Cell of Head and Neck
- Squamous Cell Carcinoma of the Head and Neck
- Squamous Cell Carcinoma, Head And Neck

## Interventions

- **BIOLOGICAL:** EGFR Antisense DNA

## Key facts

- **NCT ID:** NCT00903461
- **Lead sponsor:** University of Pittsburgh
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-04
- **Primary completion:** 2015-03
- **Final completion:** 2016-08
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** drug supply issues
- **Last updated:** 2017-02-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00903461

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00903461, "Safety and Efficacy of Radiation/Cetuximab Plus EGFR Antisense DNA for Head and Neck Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00903461. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*